Oxford Immunotec
Oxford Immunotec to Present at the 2015 Leerink Global Healthcare Conference
DGAP-News: Oxford Immunotec 2015-01-27 / 16:17 --------------------------------------------------------------------- OXFORD, United Kingdom and MARLBOROUGH, Mass., Jan. 27, 2015 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced that Peter Wrighton-Smith Ph.D., Chief Executive Officer, and Rick Altieri, Chief Financial Officer, will present at the 2015 Leerink Global Healthcare Conference at the Waldorf Astoria Hotel in New York, New York on Wednesday, February 11, 2015 at 2:40 pm ET. About Oxford Immunotec Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions. The Company's initial product is the T-SPOT(R).TB test, which is used to test for latent tuberculosis infection. The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The T-SPOT.TB test utilizes the proprietary T-SPOT technology platform that measures the responses of specific immune cells, known as T cells, to inform the diagnosis, prognosis and monitoring of patients with immunologically controlled diseases. The Company has an additional six products based on either T-SPOT or innate immunity technology platforms in various stages of development. The two most advanced products are focused on the transplantation market and test for CMV infection and organ rejection. The Company is headquartered near Oxford, UK and in Marlborough, MA. Additional information can be found at www.oxfordimmunotec.com. T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd. CONTACTS: For Media Inquiries: Caroline Crawley Oxford Immunotec Tel: +44 1235 442796 ccrawley@oxfordimmunotec.com For Investor Inquiries: Rick Altieri Chief Financial Officer, Oxford Immunotec Tel: +1 (508) 573-9953 raltieri@oxfordimmunotec.com Mark Klausner Westwicke Partners Tel: +1 (443) 213-0500 oxfordimmunotec@westwicke.com News Source: NASDAQ OMX --------------------------------------------------------------------- 2015-01-27 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: Oxford Immunotec United Kingdom ISIN: GB00BGFBB958 End of News DGAP News-Service --------------------------------------------------------------------- 316817 2015-01-27
Aktuelle News
Aktuelle Berichte
Keine Berichte gefunden
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden